Mohit Manrao: Positive high-level results from the NIAGARA Phase 3 study with IO in MIBC

Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared on LinkedIn:

“This content is for US audiences only.

The relentless pace of oncology innovation never slows down – even after AstraZeneca’s thrilling ASCO appearance just a few weeks ago.

Today, we announced positive high-level results from the NIAGARA Phase 3 study with our IO medicine demonstrating clinically meaningful and statistically significant benefits in muscle-invasive bladder cancer (MIBC).

Administering our IO therapy plus chemo as neoadjuvant treatment, then as adjuvant monotherapy after surgery led to improved event-free survival in patients with MIBC.

This cancer is hard to treat and likely to spread, so we see the promise for a more effective options in this patient population.

Pushing the boundaries of science has allowed us to begin realizing the potential of IO treatments in new tumor areas like bladder cancer.

And today’s positive readout means that we’re starting to see the impact on the patients we serve. We look forward to sharing the full results of the NIAGARA trial at a future medical conference.

Read more about the announcement.”

Source: Mohit Manrao/LinkedIn